August 13, 2021 -- Mustang Bio announced it is collaborating with the Mayo Clinic on a novel technology for CAR T-cell therapies.
The technology is a new platform that aims to administer CAR T therapy using a two-step approach. In the first step, a peptide is administered to the patient to increase the patient's resident T cells. The second step is administration of a viral CAR construct, which is inserted directly into the lymph nodes of the patient.
The viral construct infects the activated T cells and forms CAR T cells in vivo in the patient. Successful implementation of the therapy may lead to an off-the-shelf product with no need to isolate and expand patient T cells ex vivo, the company said.
Development of the technology will take place at the Mayo Clinic. Mustang plans to file an investigational new drug application for a multicenter phase I clinical trial once a lead construct has been identified.
Financial details of the partnership were not disclosed.